 | |
|
Washington: A class-action lawsuit has been filed against CVS Caremark, one of the largest pharmacy benefit managers (PBMs) in the United States, after the company decided to remove Zepbound, Eli Lilly’s GLP-1 medication for obesity, from its list of covered drugs.
According to details, the PBM stopped covering Zepbound from July 1, 2025, and instead made Wegovy, a Novo Nordisk product, the preferred option. CVS Caremark argued that the move was aimed at reducing costs, as Wegovy was available at a lower negotiated price.
However, patients claim that they were left with no choice but to switch medications despite Zepbound being more effective for many users. The lawsuit accuses CVS Caremark of “nonmedical switching,” where financial considerations were prioritized over patient health needs.
Several patients expressed frustration, saying they had achieved significant weight loss on Zepbound but were forced to change treatment. Some are now applying for medical exceptions, while others are seeking alternatives like Mounjaro.
Experts believe this case highlights the growing tension between cost-cutting strategies of PBMs and the clinical needs of patients, particularly in the expanding obesity drug market.
Post a Comment